TY - JOUR
T1 - Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus
AU - Tarragon, Ernesto
AU - Lopez, Dolores
AU - Estrada, Cristina
AU - Gonzalez-Cuello, Ana
AU - Ros, Carmen Ma
AU - Lamberty, Yves
AU - Pifferi, Fabien
AU - Cella, Massimo
AU - Canovi, Mara
AU - Guiso, Giovanna
AU - Gobbi, Marco
AU - Fernández-Villalba, Emiliano
AU - Blin, Olivier
AU - Bordet, Regis
AU - Richardson, Jill C.
AU - Herrero, María Trinidad
PY - 2014
Y1 - 2014
N2 - Memory loss is one of the key features of cognitive impairment in either aging, Mild Cognitive Impairment (MCI) or dementia. Pharmacological treatments for memory loss are today focused on addressing symptomatology. One of these approved compounds is memantine, a partial NMDA receptor antagonist that has proved its beneficial effects in cognition. The Octodon degus (O. degus) has been recently proposed as a potential model relevant for neurodegenerative diseases. However, there are no previous studies investigating the effect of pharmacological treatments for age-related cognitive impairment in this rodent. In this work we aimed to evaluate the effect of memantine on sleep deprivation (SD)-induced memory impairment in young and old O. degus. Young and old animals were trained in different behavioral paradigms validated for memory evaluation, and randomly assigned to a control (CTL, n = 14) or an SD (n = 14) condition, and treated with vehicle or memantine (10-mg/Kg i.p.) before the SD started. We demonstrate that SD impairs memory in both young and old animals, although the effect in the old group was significantly more severe (P <0.05). Memantine pretreatment was able to prevent the cognitive impairment caused by SD in both age groups, while it had no negative effect on CTL animals. The positive effect of memantine in counteracting the negative effect of SD on the retrieval process even in the aged O. degus further supports the translational potential of both the challenge and the species, and will enable a better understanding of the behavioral features of memantine effects, especially related with reference and working memories.
AB - Memory loss is one of the key features of cognitive impairment in either aging, Mild Cognitive Impairment (MCI) or dementia. Pharmacological treatments for memory loss are today focused on addressing symptomatology. One of these approved compounds is memantine, a partial NMDA receptor antagonist that has proved its beneficial effects in cognition. The Octodon degus (O. degus) has been recently proposed as a potential model relevant for neurodegenerative diseases. However, there are no previous studies investigating the effect of pharmacological treatments for age-related cognitive impairment in this rodent. In this work we aimed to evaluate the effect of memantine on sleep deprivation (SD)-induced memory impairment in young and old O. degus. Young and old animals were trained in different behavioral paradigms validated for memory evaluation, and randomly assigned to a control (CTL, n = 14) or an SD (n = 14) condition, and treated with vehicle or memantine (10-mg/Kg i.p.) before the SD started. We demonstrate that SD impairs memory in both young and old animals, although the effect in the old group was significantly more severe (P <0.05). Memantine pretreatment was able to prevent the cognitive impairment caused by SD in both age groups, while it had no negative effect on CTL animals. The positive effect of memantine in counteracting the negative effect of SD on the retrieval process even in the aged O. degus further supports the translational potential of both the challenge and the species, and will enable a better understanding of the behavioral features of memantine effects, especially related with reference and working memories.
KW - Alzheimer disease
KW - Memantine
KW - Memory
KW - Octodon degus
KW - Sleep deprivation
UR - http://www.scopus.com/inward/record.url?scp=84902474724&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902474724&partnerID=8YFLogxK
U2 - 10.1016/j.neuropharm.2014.05.023
DO - 10.1016/j.neuropharm.2014.05.023
M3 - Article
C2 - 24878242
AN - SCOPUS:84902474724
VL - 85
SP - 206
EP - 214
JO - Neuropharmacology
JF - Neuropharmacology
SN - 0028-3908
ER -